Psoriasis is a multifactorial immune-mediated disease characterized by systemic inflammation and immune dysfunction. It manifests as itchy, scaly plaques that significantly impair the quality of life and mental well-being of patients. These lesions commonly appear on the knees, elbows, trunk, and scalp. Current therapeutic approaches aim to slow excessive skin cell growth and alleviate symptoms. These include topical treatments, phototherapy, and systemic therapies such as immunosuppressants and biologics. Recent guidelines from the American Academy of Dermatology and the National Psoriasis Foundation (AAD/NPF) recommend biologics as a first-line treatment for moderate-to-severe plaque psoriasis, given their high specificity, efficacy, and safety (JAMA, 2020; 323(19):1945–1960). Consequently, biologics have become a focal point in psoriasis drug development.
As a leading preclinical CRO specializing innon-human primate (NHP) pharmacology research, Prisys Biotech excels in developing clinically relevant large-animal disease models. Our capabilities integrate in vivo pharmacology, in vitro analytical testing, and advanced pathological assessments. This comprehensive approach has enabled Prisys Biotech to pioneer the cynomolgus monkey psoriasis model, facilitating the development of next-generation therapies for psoriasis.
Development of the Cynomolgus Monkey Psoriasis Model
Prisys Biotech employs the widely recognized imiquimod (IMQ)-induced method to establish a psoriasis model. By administering a precise dose of IMQ to healthy cynomolgus monkeys, we mimic the pathological changes observed in human psoriasis. In our studies, we categorized animals into three groups: a normal control group, an IMQ-induced model group, and a treatment group receiving calcitriol. Following IMQ induction, the model and treatment groups exhibited distinct psoriasis-like lesions. Remarkably, calcitriol treatment in the positive drug group significantly ameliorated these skin abnormalities. Clinical scoring across all groups revealed significant differences, underscoring the success of the model.
Psoriasis Assessment
Pathological Insights and Clinical Relevance
To further investigate the progression of psoriasis, we collected skin samples at multiple stages: pre-induction, induction, post-induction, treatment, and post-treatment. Histological analyses revealed hallmark psoriasis features in the model and treatment groups, including inflammatory cell infiltration, parakeratosis, and hyperkeratosis. Notably, symptoms in the treatment group improved substantially after calcitriol administration, as evidenced by histopathological findings.
Histopathology findings: After IMQ topical application for 21 days
and daivobet treatment for 7 days: decrease thickness of epithelium (stratum spinosum),
reduce inflammatory cell infiltration underneath epidermis, reduce scaling,
Transforming Preclinical Drug Research
The cynomolgus monkey psoriasis model developed by Prisys Biotech effectively replicates the key pathological features of human psoriasis, making it a robust platform for preclinical drug screening and therapeutic research. This model bridges the gap between experimental findings and clinical applications, accelerating the discovery of innovative treatments for this challenging disease.
About Prisys Biotech
Prisys Biotech is a premier provider of preclinical research services with a focus on non-human primate models. Renowned for our expertise in developing disease-specific models, we enable cutting-edge research in immunology, CNS disorders, hematological diseases, and dermatology. Our real-time imaging platforms, advanced pathology capabilities, and AI-driven behavioral analysis systems set us apart as a trusted partner for pharmaceutical innovation. By combining precision, scientific rigor, and ethical compliance, Prisys Biotech continues to drive advancements in translational medicine.
